Oral antidiabetic agents: Anti-atherosclerotic properties beyond glucose lowering?

Current Pharmaceutical Design

Volumn 15, Issue 27, 2009, Pages 3179-3192

  Papanas, N ^a   Maltezos, E ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Atherosclerosis; Diabetes mellitus; Oral antidiabetic agents; Thiazolidinediones; Vascular disease

Indexed keywords

ACARBOSE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ABDOMINAL DISCOMFORT; ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANEMIA; ARTERIAL WALL THICKNESS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG RELEASE; FIBRINOLYSIS; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOLIPEMIA; LACTIC ACIDOSIS; METABOLIC REGULATION; METEORISM; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERIPHERAL EDEMA; PRIORITY JOURNAL; RESTENOSIS; REVIEW; RISK FACTOR; SIDE EFFECT; STROKE; SYSTOLIC BLOOD PRESSURE; VASCULAR DISEASE; WEIGHT GAIN;

ACARBOSE; ADMINISTRATION, ORAL; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; METFORMIN; PATIENT SELECTION; RISK ASSESSMENT; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 70449455395     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789057995     Document Type: Review

References (139)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053
2. Coliaguri S, Borch-Johnsen K, Glümer C, Vistisen D. There really is an epidemic of type 2 diabetes. Diabetologia 2005; 48: 1459-1463 (Pubitemid 41175496)
3. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004; 44: 397-405.
4. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234 (Pubitemid 28350165)
5. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
6. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853 (Pubitemid 28416718)
7. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444 (Pubitemid 23046633)
8. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393 (Pubitemid 36159355)
9. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580-591 (Pubitemid 351214285)
10. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005; 65: 385-411. (Pubitemid 40227460)
11. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2006; 49: 1711-1721
12. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2009; 52: 17-30. (Pubitemid 44025023)
13. Martens FMAC, Visseren FLJ, Lemay J, de Koning EJP, Rabelink TJ. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62: 1463-1480 (Pubitemid 34804155)
14. Ríos-Vázquez R, Marzoa-Rivas R, Gil-Ortega I, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonists for management and prevention of vascular disease in patients with and without diabetes mellitus. Am J Cardiovasc Drugs 2006; 6: 231-242 (Pubitemid 44285132)
15. Duan SZ, Usher MG, Mortensen RM. Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature. Circ Res 2008; 102: 283-294
16. Boyle PJ, King AB, Olansky L, Marchetti A, Lau H, Magar R, et al. Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records. Clin Ther 2002; 24: 378-396 (Pubitemid 34275860)
17. Blaschke F, Caglayan E, Hsueh WA. Peroxisome proliferator-activated receptor gamma agonists: their role as vasoprotective agents in diabetes. Endocrinol Metab Clin North Am 2006; 35: 561-74, ix. (Pubitemid 44335832)
18. Rizos CV, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother 2008; 9: 1087-1108
19. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289 (Pubitemid 41416583)
20. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288
21. Goldberg RB, Kendall DM, Deeg MA, Buse JB, Zagar AJ, Pinaire JA et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2005; 28: 1547-1554 (Pubitemid 40923063)
22. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober SJ et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 2007; 30: 2458-2464
23. van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 2003; 23: 1744-1749 (Pubitemid 37254857)
24. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004; 164: 2097-2104 (Pubitemid 39419498)
25. Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN et al. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial. Clin Ther 2006; 28: 679-688 (Pubitemid 44067262)
26. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383 (Pubitemid 44060202)
27. Shadid S, Jensen MD. Effects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesity. Diabetes Care 2003; 26: 3148-3152 (Pubitemid 37339512)
28. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-579
29. Musi N, Hirshman MF, Nygren J, Svanfeldt M, Bavenholm P, Rooyackers O et al. Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 2002; 51: 2074-2081 (Pubitemid 34729010)
30. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000; 348: 607-614 (Pubitemid 30410251)
31. Fantus IG. Metformin's contraindications: needed for now. CMAJ 2005; 173: 505-507
32. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865
33. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589
34. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 3: CD002966.
35. Selvin E, Bolen S, Yeh HC, Wiley C, Wilson LM, Marinopoulos SS et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med 2008; 168: 2070-2080
36. Palumbo PJ. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus. J Diabetes Complications 1998; 12: 110-119 (Pubitemid 28156441)
37. Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS. The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control. Diabetes Care 1998; 21: 701-705 (Pubitemid 28487058)
38. Fontbonne A, Charles MA, Juhan-Vague I, Bard JM, André P, Isnard F et al. The effect of metformin on the metabolic abnormalities associated with upper-body fat distribution. BIGPRO Study Group. Diabetes Care 1996; 19: 920-926 (Pubitemid 26301225)
39. Charles MA, Eschwège E, Grandmottet P, Isnard F, Cohen JM, Bensoussan JL et al. Treatment with metformin of non-diabetic men with hypertension, hypertriglyceridaemia and central fat distribution: the BIGPRO 1.2 trial. Diabetes Metab Res Rev 2000; 16: 2-7. (Pubitemid 30160610)
40. Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256: 1-14. (Pubitemid 38813614)
41. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993; 16: 621-629
42. Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism 2007; 56: 1087-1092
43. Bolen S, Feldman L, Vassy J, Wilson L, Yeh HC, Marinopoulos S et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147: 386-399 (Pubitemid 351664540)
44. Schernthaner G. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects. Metabolism 2003; 52 (8 Suppl 1): 29-34. (Pubitemid 37098387)
45. Papanas N, Tziakas D, Chalikias G, Floros D, Trypsianis G, Papadopoulou E, Kortsaris A, et al. Gliclazide treatment lowers serum ICAM-1 levels in poorly controlled type 2 diabetic patients. Diabetes Metab 2006; 32: 344-349 (Pubitemid 44410148)
46. Sliwinska A, Blasiak J, Kasznicki J, Drzewoski J. In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM). Chem Biol Interact 2008; 173: 159-165
47. Drzewoski J, Zurawska-Klis M. Effect of gliclazide modified release on adiponectin, interleukin-6, and tumor necrosis factor-alpha plasma levels in individuals with type 2 diabetes mellitus. Curr Med Res Opin 2006; 22: 1921-1926 (Pubitemid 44663396)
48. Koshiba K, Nomura M, Nakaya Y, Ito S. Efficacy of glimepiride on insulin resistance, adipocytokines, and atherosclerosis. J Med Invest 2006; 53: 87-94.
49. Pfützner A, Marx N, Lübben G, Langenfeld M, Walcher D, Konrad T et al. Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study. J Am Coll Cardiol 2005; 45: 1925-1931 (Pubitemid 40814110)
50. Mazzone T, Meyer PM, Feinstein SB, Davidson MH, Kondos GT, D'Agostino RB Sr et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA 2006; 296: 2572-2581 (Pubitemid 44903861)
51. Davidson M, Meyer PM, Haffner S, Feinstein S, D'Agostino R Sr, Kondos GT et al. Increased high-density lipoprotein cholesterol predicts the pioglitazone-mediated reduction of carotid intima-media thickness progression in patients with type 2 diabetes mellitus. Circulation 2008; 117: 2123-2130 (Pubitemid 351572171)
52. Stocker DJ, Taylor AJ, Langley RW, Jezior MR, Vigersky RA. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. Am Heart J 2007; 153: 445.e1-6
53. Osman A, Otero J, Brizolara A, Waxman S, Stouffer G, Fitzgerald P et al. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Am Heart J 2004; 147: e23. (Pubitemid 38880992)
54. Fang CC, Ng Jao YT, Yi-Chen, Yu CL, Chen CL, Wang SP. Angiographic and clinical outcomes of rosiglitazone in patients with type 2 diabetes mellitus after percutaneous coronary interventions: a single center experience. Angiology 2007; 58: 523-534
55. Takagi T, Yamamuro A, Tamita K, Yamabe K, Katayama M, Mizoguchi S, et al. Pioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning study. Am Heart J 2003; 146: E5. (Pubitemid 30825986)
56. Takagi T, Yamamuro A, Tamita K, Katayama M, Morioka S. Thiazolidinedione treatment attenuates diffuse neointimal hyperplasia in restenotic lesions after coronary stent implantation in type 2 diabetic patients: an intravascular ultrasound study. J Cardiol 2005; 45: 139-147 (Pubitemid 40756198)
57. Nishio K, Sakurai M, Kusuyama T, Shigemitsu M, Fukui T, Kawamura K, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetes. Diabetes Care 2006; 29: 101-106 (Pubitemid 44033439)
58. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573
59. Wilcox R, Bousser MG, Betteridge DJ, Schernthaner G, Pirags V, Kupfer S, et al. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 2007; 38: 865-873 (Pubitemid 46568445)
60. Erdmann E, Dormandy JA, Charbonnel B, Massi-Benedetti M, Moules IK, Skene AM; PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. J Am Coll Cardiol 2007; 49: 1772-1780 (Pubitemid 46629127)
61. Matthews DR, Tsapas A. Four decades of uncertainty: landmark trials in glycaemic control and cardiovascular outcome in type 2 diabetes. Diab Vasc Dis Res 2008; 5: 216-218
62. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI; Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288
63. Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, et al. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome. J Clin Pharm Ther 2006; 31: 375-383 (Pubitemid 44060202)
64. Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 2002; 87: 2784-2791 (Pubitemid 34655345)
65. Basu A, Jensen MD, McCann F, Mukhopadhyay D, Joyner MJ, Rizza RA. Effects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetes. Diabetes Care 2006; 29: 510-514 (Pubitemid 44115345)
66. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368: 1096-1105
67. St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002; 25: 2058-2064
68. Bakris GL, Ruilope LM, McMorn SO, Weston WM, Heise MA, Freed MI, et al. Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. J Hypertens 2006; 24: 2047-2055
69. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Liapis CD, Alevizos M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. Diabetes Med 2008; 25: 333-340 (Pubitemid 351322712)
70. Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684 (Pubitemid 34851926)
71. Kim HJ, Kang ES, Kim DJ, Kim SH, Ahn CW, Cha BS, et al. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. Clin Endocrinol (Oxford) 2007; 66: 282-289
72. Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus- an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis 2008; 197: 718-724
73. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ. Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 2005; 46: 773-778
74. Martens FM, Rabelink TJ, Roodt J, de Koning EJ, Visseren FL. TNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazone. Eur Heart J 2006; 27: 1605-1609 (Pubitemid 43954922)
75. Wang CH, Ting MK, Verma S, Kuo LT, Yang NI, Hsieh IC, et al. Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus. Am Heart J 2006; 152: 1051.e1-8
76. Hetzel J, Balletshofer B, Rittig K, Walcher D, Kratzer W, Hombach V, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005; 25: 1804-1809 (Pubitemid 41243446)
77. Borchert M, Schöndorf T, Lübben G, Forst T, Pfützner A. Review of the pleiotropic effects of peroxisome proliferator-activated receptor gamma agonists on platelet function. Diabetes Technol Ther 2007; 9: 410-420 (Pubitemid 47585354)
78. Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol 2007; 27: 2428-2434 (Pubitemid 350203960)
79. Adams M, Montague CT, Prins JB, Holder JC, Smith SA, Sanders L, et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J Clin Invest 1997; 100: 3149-3153 (Pubitemid 28022853)
80. Forst T, Pfützner A, Lübben G, Weber M, Marx N, Karagiannis E, et al. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk- the PIOSTAT Study. Metabolism 2007; 56: 491-496 (Pubitemid 46437254)
81. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004;147: e25
82. Szapary PO, Bloedon LT, Samaha FF, Duffy D, Wolfe ML, Soffer D, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 182-188 (Pubitemid 43732247)
83. Esposito K, Ciotola M, Carleo D, Schisano B, Saccomanno F, Sasso FC, et al. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care 2006; 29: 1071-1076 (Pubitemid 44115246)
84. Sidhu JS, Cowan D, Tooze JA, Kaski JC. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone reduces circulating platelet activity in patients without diabetes mellitus who have coronary artery disease. Am Heart J 2004;147: e25 (Pubitemid 38880959)
85. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, et al. Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531-2538 (Pubitemid 44881227)
86. Sidhu JS, Cowan D, Kaski JC. The effects of rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, on markers of endothelial cell activation, C-reactive protein, and fibrinogen levels in non-diabetic coronary artery disease patients. J Am Coll Cardiol 2003; 42: 1757-1763 (Pubitemid 37433654)
87. Sidhu JS, Cowan D, Kaski JC. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus. Am J Cardiol 2004; 94: 151-156 (Pubitemid 38902860)
88. Marx N, Wöhrle J, Nusser T, Walcher D, Rinker A, Hombach V, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005; 112: 2792-2798 (Pubitemid 41641673)
89. Katayama T, Ueba H, Tsuboi K, Kubo N, Yasu T, Kuroki M, et al. Reduction of neointimal hyperplasia after coronary stenting by pioglitazone in nondiabetic patients with metabolic syndrome. Am Heart J 2007; 153: 762.e1-7 (Pubitemid 46604810)
90. Zeymer U. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes. Int J Cardiol 2006; 107: 11-20. (Pubitemid 41767513)
91. DECODE Study Group. Is fasting glucose sufficient to define diabetes? Epidemiological data from 20 European studies. Diabetologia 1999; 42: 647-654
92. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular causes? Diabetes Care 2003; 26: 688-696
93. Wolever TM, Chiasson JL, Csima A, Hunt JA, Palmason C, Ross SA, et al. Variation of postprandial plasma glucose, palatability, and symptoms associated with a standardized mixed test meal versus 75 g oral glucose. Diabetes Care 1998; 21: 336-340 (Pubitemid 28101065)
94. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001; 414: 813-820 (Pubitemid 34000785)
95. Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280: C719-41. (Pubitemid 32472311)
96. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687
97. Chiasson JL, Gomis R, Hanefeld M, Josse RG, Karasik A, Laakso M. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus. Diabetes Care 1998; 21: 1720-1725 (Pubitemid 28449814)
98. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486-494
99. Zeymer U, Schwarzmaier-D'assie A, Petzinna D, Chiasson JL; STOP-NIDDM Trial Research Group. Effect of acarbose treatment on the risk of silent myocardial infarctions in patients with impaired glucose tolerance: results of the randomised STOP-NIDDM trial electrocardiography substudy. Eur J Cardiovasc Prev Rehabil 2004; 11: 412-415
100. Hanefeld M, Chiasson JL, Koehler C, Henkel E, Schaper F, Temelkova-Kurktschiev T. Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance. Stroke 2004; 35: 1073-1078 (Pubitemid 38543520)
101. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25: 10-16 (Pubitemid 38055587)
102. Rosenbaum P, Peres RB, Zanella MT, Ferreira SR. Improved glycemic control by acarbose therapy in hypertensive diabetic patients: effects on blood pressure and hormonal parameters. Braz J Med Biol Res 2002; 35: 877-884 (Pubitemid 35390339)
103. Rosenthal JH, Mauersberger H. Effects on blood pressure of the alpha-glucosidase inhibitor acarbose compared with the insulin enhancer glibenclamide in patients with hypertension and type 2 diabetes mellitus. Clin Drug Investig 2002; 22: 695-701. (Pubitemid 35155504)
104. Scott R, Lintott CJ, Zimmet P, Campbell L, Bowen K, Welborn T. Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus? Diabetes Res Clin Pract 1999; 43: 179-185
105. Kado S, Murakami T, Aoki A, Nagase T, Katsura Y, Noritake M, et al. Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus. Diabetes Res Clin Pract 1998; 41: 49-55. (Pubitemid 28394284)
106. Chiasson JL, Josse RG, Leiter LA, Mihic M, Nathan DM, Palmason C, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19: 1190-1193 (Pubitemid 26363430)
107. Delgado H, Lehmann T, Bobbioni-Harsch E, Ybarra J, Golay A. Acarbose improves indirectly both insulin resistance and secretion in obese type 2 diabetic patients. Diabetes Metab 2002; 28: 195-200. (Pubitemid 34746953)
108. Salman S, Salman F, Satman I, Yilmaz Y, Ozer E, Sengül A, et al. Comparison of acarbose and gliclazide as first-line agents in patients with type 2 diabetes. Curr Med Res Opin 2001; 16: 296-306. (Pubitemid 32221487)
109. Ceriello A, Taboga C, Tonutti L, Giacomello R, Stel L, Motz E, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-473 (Pubitemid 26093875)
110. Hanefeld M, Schaper F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. Expert Rev Cardiovasc Ther 2008; 6: 153-163
111. Chiasson JL. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr Pract 2006; 12 Suppl 1: 25-30. (Pubitemid 44963607)
112. Johansen OE, Birkeland KI. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Am J Cardiovasc Drugs 2007; 7: 319-335 (Pubitemid 47624536)
113. Manzella D, Grella R, Abbatecola AM, Paolisso G. Repaglinide administration improves brachial reactivity in type 2 diabetic patients. Diabetes Care 2005; 28: 366-371 (Pubitemid 40170941)
114. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-484 (Pubitemid 36286914)
115. Yngen M, Ostenson CG, Hjemdahl P, Wallén NH. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide. Diabet Med 2006; 23: 134-140
116. Schmoelzer I, Wascher TC. Effect of repaglinide on endothelial dysfunction during a glucose tolerance test in subjects with impaired glucose tolerance. Cardiovasc Diabetol 2006; 5: 9.
117. Rizzo MR, Barbieri M, Grella R, Passariello N, Paolisso G. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study. Diabetes Metab 2005; 31: 255-260 (Pubitemid 40961522)
118. Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 2004; 110: 214-219
119. Mita T, Watada H, Shimizu T, Tamura Y, Sato F, Watanabe T, et al. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. Arterioscler Thromb Vasc Biol 2007; 27: 2456-2462 (Pubitemid 350203964)
120. Abbatecola AM, Rizzo MR, Barbieri M, Grella R, Arciello A, Laieta MT, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67: 235-240 (Pubitemid 44305405)
121. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin. Diabetes Res Clin Pract 2003; 60: 161-169 (Pubitemid 36561617)
122. Rizzo MR, Barbieri M, Grella R, Passariello N, Barone M, Paolisso G. Repaglinide is more efficient than glimepiride on insulin secretion and post-prandial glucose excursions in patients with type 2 diabetes. A short term study. Diabetes Metab 2004; 30: 81-89 (Pubitemid 38418947)
123. Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Frandsen M, Smidt UM, et al. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. Diabetes Obes Metab 2007; 9: 394-407. (Pubitemid 46502060)
124. Derosa G, D'Angelo A, Fogari E, Salvadeo S, Gravina A, Ferrari I, et al. Effects of nateglinide and glibenclamide on prothrombotic factors in naïve type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. Intern Med 2007; 46: 1837-1846 (Pubitemid 350200169)
125. Holstein A, Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005; 48: 2454-2459
126. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007; 356: 2457-2471 (Pubitemid 46919772)
127. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195 (Pubitemid 47403105)
128. Rottlaender D, Michels G, Erdmann E, Hoppe UC. Thiazolidinedione derivatives- a risk for cardiovascular disease? Dtsch Med Wochenschr 2007; 132: 2629-2632
129. Gerrits CM, Bhattacharya M, Manthena S, Baran R, Perez A, Kupfer S. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf 2007; 16: 1065-1071 (Pubitemid 350020057)
130. Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, et al. Rosiglitazone evaluated for cardiovascular outcomes- an interim analysis. N Engl J Med 2007; 357: 28-38. (Pubitemid 47026732)
131. Rohatgi A, McGuire DK. Effects of the thiazolidinedione medications on micro- and macrovascular complications in patients with diabetes- update 2008. Cardiovasc Drugs Ther 2008; 22: 233-240
132. Khanderia U, Pop-Busui R, Eagle KA. Thiazolidinediones in type 2 diabetes: a cardiology perspective. Ann Pharmacother 2008; 42: 1466-1474
133. Grant PJ. Rosiglitazone and cardiovascular disease: a diabetologist's perspective. Diab Vasc Dis Res 2007; 4: 75-76 (Pubitemid 47167487)
134. Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008; 5: 116-120
135. Koro CE, Fu Q, Stender M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. Pharmacoepidemiol Drug Saf 2008; 17: 989-996
136. Monami M, Marchionni N, Mannucci E. Winners and losers at the rosiglitazone gamble. A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. Diabetes Res Clin Pract 2008; 82: 48-57.
137. Kalaitzidis RG, Sarafidis PA, Bakris GL. Effects of thiazolidineiones beyond glycaemic control. Curr Pharm Des 2009; 15(5): 529-536
138. Motta DA. Metformin in the treatment of polycystic ovary syndrome. Curr Pharm Des 2008; 14(21): 2121-2125
139. Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. Prog Drug Res 2008; 65: 45, 47-118.